Resistance mechanisms and post-trastuzumab deruxtecan (T-DXd) strategies in HER2+ and HER2-low breast cancer: From biology to clinical practice

Key Points

• Resistance mechanisms can lead to treatment failure in HER2+ breast cancer, complicating effective management.
• Key findings show that post-trastuzumab deruxtecan strategies may enhance therapeutic effectiveness by targeting specific pathways.
• Focused analysis explores biomarker-driven approaches to refine treatment plans for HER2-positive and HER2-low patients.
• Insights into clinical practice underscore the importance of understanding drug resistance in personalizing breast cancer therapies.